Kyle Doherty

Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.

Data presented at 2022 SGO from the phase 2 OVARIO trial show promise of niraparib plus bevacizumab in high-risk ovarian cancer treated with frontline platinum-based chemotherapy.

Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.

Daniel P. Petrylak, MD, reviews the current systemic therapy treatment paradigm in metastatic urothelial carcinoma.

Patients with metastatic castration-sensitive prostate cancer experienced an early and robust reduction in prostate-specific antigen of 90% or more following treatment with apalutamide vs enzalutamide.

YTB323 led to a promising safety profile and encouraging efficacy outcomes for adult patients with relapsed/refractory diffuse large B-cell lymphoma.

A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated with duvelisib plus romidespin.

A quality-of-life analysis from the phase 3 ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma shows favorability of the CAR T-cell therapy over standard options.

Patients with relapsed or refractory follicular lymphoma who had been given 2 or more prior lines of therapy and received tisagenlecleucel saw positive efficacy responses.

Second-line treatment with liscocabtagene maraleucel improved survival compared with the standard of care for patients with relapsed or refractory large B-cell lymphoma.

Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.

Results of a single-arm study indicate that patients with previously treated metastatic cervical cancer may derive benefit from treatment with balstilimab plus zalifrelimab.

Erdafitinib plus cetrelimab displayed strong responses for patients with metastatic or locally advanced urothelial carcinoma.

Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.

CAR066, showed a favorable safety profile and promising efficacy in the treatment of adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed prior CD19 CAR T-cell therapy.

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

For patients with NRG1 fusion–positive cancers, zenocutuzumab represents a promising novel targeted therapeutic option.

Patients with advanced synovial sarcoma who received treatment with catequentinib experienced improved disease control and progression-free survival compared with dacarbazine.

The clinical benefit rate of the neratinib plus fulvestrant combination treatment did not meet the predefined efficacy threshold, but was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer.